Ovarian Cancer: Diagnosis and Treatment
HANS-L. KOTTMEIER

Department of Gynaecology, Radiumhemmet, Karolinska Institute,
Stockholm, Sweden

Ovarian cancer is not an entity
but a group of diseases. Studies of
the result of treatment must be
based on homogenous groups of
tumors and not on mixtures of histologically and biologically different tumor types. Furthermore,
there still exists a considerable degree of confusion as to which tumors should be considered true
carcinomas. Experience has shown
that between obviously benign and
obviously malignant neoplasms
there exists a group of well-differentiated tumors that, in their clinical behavior, resemble true carcinomas, inasmuch as they give rise
to implantation metastases and
ascites and cause the death of the
patient, but yet have quite a different course. The lack of generally
accepted definitions of the various
histological forms has resulted in
the extreme differences in longterm results given by various authors. The importance of elaborating a standardized, internationally
accepted classification of ovarian
tumors so that the results of different clinics may be accurately
compared is obvious. The International Federation of Gynecology
and Obstetrics has adopted a histopathologic classification of ovarian
tumors related to the Miillerian
epithelium. They consist of the
serous, mucinous, and endometrioid
types. The so-called endometrioid
carcinomas resemble adenocarcinoma of the endometrium. In general they are well differentiated,
while the majority o~ serous carciMCY QUARTERLY 3(1): 47-53, 1967

nomas are more or less undifferentiated.
Table 1 gives the histologic classification of the primary epithelial
tumors. Figure 1 presents the survival rates of serous cystomas.
From the figures given it is obvious
that well-differentiated tumors of
low potential malignancy ought to
be separated from true carcinomas.
We all share the opinion that, in
general, the prognosis is poor.
Ovarian carcinomas are frequently
not discovered until the growth has
extended to surrounding organs or
has given rise to metastases. The
treatment becomes progressively
less effective with increasing anatomic extent of the disease.
The necessity of an early diagnosis is obvious. Laparoscopy has
proved to be of value in many cases
and can promote an early diagnosis. Hysterosalpingography, arteriography, and needle biopsies
through the vagina or the rectum
may help in this respect. The routine use of cul de sac aspiration
may result in the detection of occult carcinomas as brilliantly demonstrated by the Grahams ( 1964) .
Sometimes a laparotomy is necessary to permit a final diagnosis.
Explorative laparotomy facilitates the outlining of the borders
of growth by direct inspection and
palpation, and should be routinely
carried out whenever there is the
slightest suspicion of an ovarian tumor. Some years ago gynecologists
considered it appropriate to apply
conservative treatment in patients

with physiologic enlargements or
cysts of the ovary. It is often difficult to decide whether an enlargement of the ovary is physiologic or
neoplastic. Since today laparotomy
is quite a safe procedure, it is wise
to perform this operation on the
slightest suspicion of an ovarian
neoplasm.
Surgery

During laparotomy the surgeon
should outline in detail the extension of the growth and take several,
rather large, biopsies from areas
that seem to be suspicious. The establishment of the anatomical extent of the carcinoma is important
in planning further therapy. Experience has proved that serous carcinomas grow fast and give rise to
extensive metastases at an early
stage, whereas mucinous tumors
are confined to the ovary for a long
time, and endometrioid carcinomas
tend to be multicentric, but remain
to the true pelvis for a long time.
Metastases above the pelvis were
diagnosed in 147 of 276 cases
(53.3 % ) of serous carcinoma, in
9 of 51 cases ( 17.6% ) of mucinous
carcinoma, and in 29 of 168 cases
(17 .2 % ) of endometrioid carcinoma. The carcinoma was limited
to the ovaries and uterus in 55 of
276 cases (19.9 % ) of serous neoplasm, in 30 of 51 cases (58.8%)
of mucinous neoplasm, and in 58
or 168 cases ( 34.5 % ) of endometrioid neoplasm.
It should be stressed, though,
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TABLE 1
Histologic Classification of Common Primary Epithelial Tumors of the Ovary
I.

Serous cystomas
a. Serous benign cystadenoma.
b. Serous cystadenomas with proliferating activity of the epithelial cells
and nuclear abnormalities, but with no infiltrative destructive growth
(low potential malignancy).
c. Serous cystadenocarcinomas.

II. Mucinous cystomas
a. Mucinous benign cystadenomas.
b. Mucinous cystadenoma~ with proliferating activity of epithelial cells
and nuclear abnormalities, but with no infiltrative destructive growth
(low potential malignancy).
c. Mucinous cystadenocarcinomas.
III. Endometrioid tumors (similar to adenocarcinomas in the endometrium)
a. Endometrioid benign cysts.
b. Endometrioid tumors with proliferating activity of the epithelial cells
and nuclear abnormalities, but with no infiltrative destructive growth
(low potential malignancy).
c. Endometrioid adenocarcinomas.
IV. Concomitant carcinoma, unclassified carcinoma
Tumors which cannot be allotted to one of the groups I, II, or III.
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Fig. 1-Ten-year survival rates of cystomas (375 cases).
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that the excision of an ovarian carcinoma should be performed to the
greatest possible extent. Every effort should be made to keep the
capsula intact. Even if the tumor
is unilateral, it is advisable to remove the opposite ovary. In young
patients and in those who want to
have children, a unilateral oophorectomy may be considered. If,
however, the tumor is a serous type,
a relaparotomy is indicated, as the
normal ovary may frequently harbor microscopic metastases.
An extended operation, for instance with resection of the small
or large bowel, is indicated at least
in carcinomas that are likely to be
mucinous, as at a late stage these
neoplasms give rise to metastases
and evidently are radioresistant.
Whether this management is advisable in serous and endometrioid
carcinomas is doubtful. It is our
experience that extensive surgery
in such neoplasms smears cancer
cells over the peritoneum, opens
lymph and blood vessels, and favors
implantations and metastases. The
removal of serous or endometrioid
carcinomas fixed to surrounding
tissue by firm adhesions destroys
the defensive reaction of the body.
Recurrences appear rapidly and do
not, as a rule, respond to radiation,
nor to any other therapy. Although
we cannot prove so at present, it
seems logical to try radiotherapy
prior to excisional surgery. Consequently, the laparotomy should be
restricted to an exploratory operation. Biopsies should be taken and
irradiation administered to the area
outlined on surgery. It is not appropriate to exceed a dose of 4,000
rad in five weeks. Re-operation
should be carried out 10 to 14 days
after completion of radiotherapy.
Most gynecologists prefer to perform a panhysterectomy in addition to oophorectomy because of
possible transtubal metastases to
the endometrium. I am not convinced that, as a rule, a hysterectomy is to be recommended. Intrauterine application of radioactive
sources renders a treatment to the
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cul de sac possible. Metastases or
pelvic recurrences appear first and
foremost in the cul de sac. A heavy
dose of radiation can be given to
this area if external irradiation is
combined with intrauterine radium.
Insertion of radium into the vagina
is not valuable.
Resection of the omentum has
been recommended whenever any
surgical procedure for ovarian cancer is performed. Metastases to the
omentum are diagnosed in many
cases. At Radiumhemmet we have
not been convinced that prophylactic omentectomy is valuable and
will improve the outcome. In cases
of metastases to the omentum, a
resection lessens the degree of
ascites accumulation. Yet, a stipulation is that a cutting of the omentum is not made through carcinomatous tissue.

Application of Radioactive
Sources
lntraperitoneal examination or
removal of an ovarian carcinoma
will spread cancer cells to various
parts of the peritoneal cavity. It
is likely that such superficial peritoneal transplants are eradicated by
the intraperitoneal application of
colloidal radioactive sources. Millier ( 1959) has for years applied
radioactive gold intraperitoneally
after surgery. His results support
the value of this method. Radiumhemmet, and many others, has
substituted chemotherapeutic agents
such as Nitrogen mustard, ThioTEPA, Cytoxan, etc., for the isotope. The effect of intra-abdominal
application of isotopes or of chemical drugs has so far not been as
satisfactory as we had expected.
Radiation Therapy
The survival rate in true ovarian
carcinoma is dependent on the anatomical extent of the carcinoma.
Serous carcinomas have a tendency
to give metastases above the pelvis
and distant metastases, while en-

dometrioid carcinomas are often
limited to the pelvis. Radiation
should start as soon as possible
after surgery if laparotomy and further examination have proved that
the cancer is incompletely removed,
but yet is limited to the true pelvis.
Many authors have reported an increase of survivors if radiotherapy
is given postoperatively. At Radiumhemmet a five-year survival rate
of 17 .1 % has been reached in 35
cases of serous, and 50.0 % in 24
cases of endometrioid carcinoma
with non-resectable metastases in
the true pelvis. The corresponding three-year survival rates are
23.6% in 55 cases of serous, and
50.0% in 50 cases of endometrioid
carcinoma. These figures suggest
that endometrioid carcinomas do
respond better to irradiation than
serous ones.
In these patients conventional xray therapy with a half value layer
of 1 to 2 mm Cu has been administered through two large opposing
fields in addition to intrauterine application of radium.
Irradiation of the pelvis can be
achieved more efficiently with supervoltage radiation than with conventional roentgen therapy. As a
consequence of our experience that
endometrioid carcinomas possibly
respond better to irradiation than
serous carcinomas do, cases of
serous and endometrioid neoplasms
with extension to tissues in the true
pelvis are at present receiving cobalt beam therapy with a dose of
4,500 to 5,000 rad to the midpelvis
over a period of six to seven weeks.
Two large opposing portals or a
three-field technique are being used
in these cases. The latter method is
chosen for cases in which the extent of the carcinoma is outlined in
detail, and, thus, a reduced dose
can be given to the bladder, rectum, and small bowel partly with
the use of wedge-filters. The radiation is delivered through one large
anterior and two lateral fields.
The radiation technique mentioned is applied also in cases of
true ovarian carcinoma in which

the tumor was removed completely.
However, in such cases the dose
from external radiation is decreased
to about 3,000 rad.
The radiation therapy described
has been used at Radiumhemmet
since 1964. For the time being it is
impossible to draw any conclusions,
but we do believe that results will
be improved.
I have mentioned previously that
at Radiumhemmet radiotherapy
was also given to cases of true
ovarian carcinoma with metastases
above the pelvis. Only two of 114
such patients with serous carcinoma
are living symptom-free at five
years. The corresponding number
of endometrioid carcinoma is four
of 24. It is likely that radiotherapy
will bring about a palliation in advanced cases of true ovarian carcinomas, but it is questionable
whether the five-year survival in six
of 138 cases can be attributed to
the radiation delivered in rather
small doses. Possibly, the survival
is due to a slow growth of the disease. However, we have tried recently to deliver dosages of 3,500
to 5,000 rad to the total abdominal
cavity in selected cases of ovarian
carcinoma with extensive metastases over the entire peritoneal cavity.
The radiation h as been applied
through six fields with central doses
of 700 rad over a period of five
days. Remarkably enough the patients have withstood the radiation
satisfactorily. Their general condition has improved, the ascites has
disappeared, and sometimes the tumor has decreased considerably in
size. However, it is yet doubtful
whether the survival in cases of
serous carcinoma has been prolonged. Such a radiation as mentioned may be tried as an experiment but should not be applied
routinely.
Another attempt to increase the
dose to the entire abdomen has
been made at the M. D . Anderson
Hospital, Houston. Megavoltage irradiation was given through multiple narrow horizontal strips. Actually, this is a modification of the
49

OVARIAN CANCER: DIAGNOSIS AND TREATMENT

overlapping x-ray strip technique
recommended by Patterson for radiation of the trunk. The realization of this radiation technique is
difficult in cases of carcinoma with
ascites.
Table 2 gives the survivals in
555 cases of ovarian carcinoma
treated five years ago or earlier.
Chemotherapy
Great attention has been drawn
to radiomimetic substances in the
hope that they may delay the
growth of the carcinoma. Experience has shown that the use of
compounds similar to Nitrogen
mustard have been a success in
causing regression of ovarian carcinoma. Since the publications by
Bateman (1955; Bateman and Winship, 1956) and others, Thio-TEPA
has been reported to be useful in
the management of ovarian carcinomas, but Chlorambucil, E-39,
Endoxan, Sarcolysin, Hemisulphur
mustard, etc., have also produced
good palliation in many cases. At
Radiumhemmet we have chosen
Thio-TEPA in the treatment of
ovarian carcinoma and have used it
exclusively or in combination with
irradiation.
The intracavitary application of
cytotoxic agents has also been used
to a large extent at Radiumhemmet.
For years we nourished the hope
that intraperitoneal instillation of
Nitrogen mustard or similar drugs
would lead to palliative results similar to those achieved by colloidal

radioactive substances. Unfortunately, experience has shown that
this does not hold valid for ascites.
Nor does prophylactic installation
of Thio-TEP A into the peritoneal
cavity after laparotomy seem to be
valuable, whether it is administered
continuously or by injection.
From 1960 through 1962, an investigation was carried out to explore whether chemotherapy given
in addition to radiation would improve survival rates (Kottmeier,
1967). Thio-TEPA was given intravenously in moderate doses in
32 cases in which the ovarian carcinoma had been incompletely removed, but no extrapelvic metastases were traced. The follow-up of
these cases has not revealed any
benefit attributable to chemotherapy.
With the purpose of studying the
effect on cases of ovarian carcinoma that were either completely
inoperable or had given rise to
several unresectable metastases
above the pelvis, Thio-TEPA was
injected intravenously in 131 patients, whereas 88 patients received
only radiation. The aim was to
maintain a combined therapy until
depression of the bone marrow had
appeared. In 42 of the 131 patients,
therapy was given until the leucocytes and thrombocytes were depressed to very low levels. Table 3
presents the distribution of the cases
in regard to the histopathological
type of the growth. The serous carcinomas amount to 38% in the irradiated group and 56% in that

TABLE 2
Five-Year Survival of Patients with Ovarian Carcinomas
No. Patients Surviving After:
Type of
Carcinoma

No. Patients
Treated

1 yr.

2 yrs.

3 yrs.

4 yrs.

5 yrs.

Serous
Mucinous
Endometrioid
Unclassified

276
51
168
60

149
39
138
29

95
35
115
18

68
33
106
17

48
32
102
14

41
32
93
13
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which had received combined therapy.
From the study (Fig. 2, table
4) it is obvious that combined
treatment has proved to be effective in producing a prolonged survival and a noticeable subjective
improvement in many cases of extensive ovarian carcinoma in which
chemotherapy was given in large
doses.
As a consequence of this trial we
give Thio-TEPA intravenously to
patients with extensive ovarian carcinoma, especially if the growth is
the serous type. It is important to
continue chemotherapy until a depression of the bone marrow occurs. It is, therefore, not sufficient
to keep the blood count under close
observation. Repeated bone marrow biopsies must be made during
the course of therapy, especially as
occasionally the blood count does
not correspond to the cellular pattern of the bone marrow taken
from the sternum.
Thio-TEP A is given intravenously with a dose of 10 mg daily or
every second day. The initial dose
varies considerably. The patient is
kept under close observation also
for several weeks after the completion of therapy, as a severe late depression of the leucocytes and
platelets may sometimes occur two
to four weeks later. The patients
have a depressed immunity to infections. The treatment involves a
risk of aplastic marrow or septicaemia. Five patients have died as a
sequel of therapy.
For the time being we do not
know whether a combined treatment of irradiation and chemotherapy is preferable to chemotherapy
alone in cases of true ovarian carcinoma with extension above the
pelvis. We suppose that a combined treatment is appropriate in
cases of endometrioid carcinoma.
In this respect I call attention to
the fact that therapy should begin
with radiation, and chemotherapy
should be given subsequently. Investigations carried out have shown
that apparent hyperplasia of the
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cellular pattern in marrow from
the sternum occurs during the first
two weeks of irradiation.
Recent observations support the
opinion that chemotherapy alone
is preferable to combined treatment in cases of extensive serous
and mucinous carcinomas. Provided initial treatment has yielded
a good effect, further chemotherapy with Thio-TEP A or E ndoxan
in moderate doses should be given,
under observation, though, of the
blood count. In our experience,
however, the platelets will never
return to normal level. In addition
blood transfusions and testosterone
in large doses should be given.

TABLE 3
Histopathological Distribution of 219 Cases of Inoperable
Ovarian Carcinoma. Results of Treatment with Irradiation
Alone and in Combination with Chemotherapy
Treatment Applied
Irradiation and
Chemotherapy

Irradiation
Pathologic Type

No.

Cases

No.

Cases

Serous
Mucinous
Endometrioid
Unclassified
No microscopic
examination

33
2
15
14

(38%)

(56%)

(17%)
(16%)

74
1
18
22

24

(27%)

16

(12%)

Total

88

(14%)
(17%)

131

Repeated Surgery
One important question remains:
Should surgery be carried out in
cases of extensive ovarian carcinoma that, on initial examination
and/ or laparotomy, were considered completely inoperable and that
had responded satisfactorily to
treatment applied? Radiumhemmet
has advocated for years that in
these cases a laparotomy should be
made with removal of as much of
the disease as is possible. In the
years 1958 through 1962, this was
carried out in 45 cases of serous
carcinoma, in eight cases of endometrioid carcinoma, and in 10
cases of unclassified true carcinoma. Six, two, and three patients
respectively have survived three
years after initial therapy. Five patients are living at five years; only
one survived of the 45 patients with
serous carcinoma. However, in 24
of the 63 patients operated upon,
the disease exploded following surgery. As a consequence of these
poor results, we only occasionally
advocate surgery in cases of extensive ovarian carcinoma that
from the beginning are considered
completely inoperable. However,
we do agree with Rutledge that
modern therapy with application
of chemical drugs in repeated series may widen the indications for
repeated surgery.
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Fig. 2-Inoperable ovarian carcinomas, 1960-1962. A randomized study to
establish the value of chemotherapy as an adjunct to irradiation.
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TABLE 4
Sustained Palliation in 219 Cases of
Inoperable Carcinoma of the Ovary
Irradiation and
Irradiation Chemotherapy
No. Cases

No. Cases

Effect

47
41

17
116

None
Good

Ovarian Carcinoma of Low
Potential Malignancy

Regarding 121 cases of so-called
" questionable" carcinomas treated
five years ago and 15 6 cases treated
at least three years ago, I have not
much to add. In cases of unilateral
growth, surgery with preservation
.o f the normal ovary may be adequate therapy. Radical excision is
important especially in cases of
mucinous tumor, as fragments of
neoplastic tissue left behind may
lead to pseudomyxoma peritonaei.
Radiotherapy with doses not ex·c eeding 3,000 rad is expedient in
all other cases in which the tumor
.could not be completely removed.
Relaparotomy is indicated in cases
inoperable
considered
initially
which improved after radiation
therapy. A five-year survival rate
of 79.6% has been attained in 49
cases of low potential carcinomas
with metastases. The corresponding
three-year survival rate in 67 cases
is 85.1 % .
Summary

I have made it my task with this
paper to outline principles for the
treatment of ovarian carcinoma.
Emphasis has been laid on pathology and on anatomical extent of
the growth. The extension of the
tumor should be outlined in detail
.at clinical examination and at laparotomy. Excision of the carcinoma
s hould be performed to the greatest
possible extent. Every effort should
be made to keep the capsule intact.
.52

In cases of serous and endometrioid carcinoma fixed to surrounding tissue by firm adhesions, it may
be appropriate to restrict the operation to an explorative laparotomy
and to operate on the patient again
10 to 14 days after completion of
radiation.
Intraperitoneal application of colloidal radioactive sources following
surgery seems to decrease the risk
of peritoneal implements and is superior to radiomimetic substances
in the palliation treatment of ascites. Removal of the primary malignancy is occasionally followed by
regression of disseminated metastases.
Radiotherapy with adequate
doses should be administered to all
cases of true ovarian carcinoma
limited to the pelvis. Endometrioid
carcinomas may respond better to
radiation than serous tumours. In
advanced cases of carcinoma with
unresectable metastases above the
pelvis, chemotherapy should be administered either as the only treatment or in combination with radiation. Chemotherapy should be
applied in doses that lead to depression of the bone marrow. Recent experience has shown that
many times the palliative effect
from chemotherapy is superior to
that from radiotherapy.
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